Cargando…

Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling

Molecular targeting therapies often cause characteristic adverse effects, such as skin rash during anti-epidermal growth factor receptor (EGFR) therapies, making treatment continuation difficult. In contrast, skin symptoms induced by EGFR inhibition are strongly correlated with the overall survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishiya, Naoyuki, Murai, Moeka, Hosoda, Ayumi, Yonezawa, Honami, Omori, Norikazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958386/ https://www.ncbi.nlm.nih.gov/pubmed/31703435 http://dx.doi.org/10.3390/ph12040165

Ejemplares similares

Bucillamine‐induced interstitial pneumonitis
por: Nakamoto, Keitaro, et al.
Publicado: (2018)

Adding Cases to the Study of Bucillamine-Associated Neural Epidermal Growth Factor-Like1-Positive Membranous Nephropathy
por: Takahashi-Kobayashi, Mayumi, et al.
Publicado: (2023)

Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor
por: Nishiya, Naoyuki, et al.
Publicado: (2021)

Bucillamine‐induced yellow nail syndrome
por: Tanizaki, Ryutaro, et al.
Publicado: (2017)

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2017)

Bucillamine prevents cisplatin-induced ototoxicity through induction of glutathione and antioxidant genes
por: Kim, Se-Jin, et al.
Publicado: (2015)

Response to Letter to the Editor entitled “Adding Cases to the Study of Bucillamine-Associated Neural Epidermal Growth Factor Like1-Positive Membranous Nephropathy”
por: Ueda, Hiroyuki
Publicado: (2023)

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
por: Wu, Shang-Gin, et al.
Publicado: (2020)

A Case of BOOP Developed during Bucillamine Treatment for Rheumatoid
por: Lee, Young Ho, et al.
Publicado: (2001)

Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay
por: Kimura, Shinichi, et al.
Publicado: (2018)

HLA-DRB1*08:02 Is Associated with Bucillamine-Induced Proteinuria in Japanese Rheumatoid Arthritis Patients
por: Furukawa, Hiroshi, et al.
Publicado: (2014)

Long‐term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation‐positive lung adenocarcinoma
por: Shijubou, Naoki, et al.
Publicado: (2021)

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Dong, Wei, et al.
Publicado: (2022)

Bucillamine in the treatment of patients with mild to moderate COVID-19: an interview with Michael Frank
por: Frank, Michael
Publicado: (2022)

Comparative proteomic analysis of glomerular proteins in primary and bucillamine-induced membranous nephropathy
por: Kaga, Hajime, et al.
Publicado: (2022)

Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer
por: Sano, Kazumi, et al.
Publicado: (2020)

Heterogeneity response to afatinib in gastric cancer patient with uncommon epidermal growth factor receptor (EGFR) mutations: a case report
por: Liu, Qin, et al.
Publicado: (2021)

Bucillamine-Induced Pemphigus Vulgaris in a Patient with Rheumatoid Arthritis and Polymyositis Overlap Syndrome
por: Hur, Jin-Wuk, et al.
Publicado: (2006)

Hyperplasia of Lymphoid Follicles and Lymphangiectasia in the Parietal Pleura in Bucillamine-induced Yellow Nail Syndrome
por: Hase, Isano, et al.
Publicado: (2018)

Afatinib-induced severe esophagitis in a lung cancer patient with an activated epidermal growth factor receptor mutation: A case report
por: Inoue, Takako, et al.
Publicado: (2017)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
por: Morin-Ben Abdallah, Sami, et al.
Publicado: (2017)

Molecularly Targeted Photothermal Ablation of Epidermal Growth Factor Receptor-Expressing Cancer Cells with a Polypyrrole–Iron Oxide–Afatinib Nanocomposite
por: Rethi, Lekshmi, et al.
Publicado: (2022)

Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib
por: Ikeuchi, Tomoyuki, et al.
Publicado: (2019)

Hypotension from afatinib in epidermal growth factor receptor-mutated non-small cell lung cancer: a case report and literature review
por: Tang, Zhiwei, et al.
Publicado: (2021)

Toxic epidermal necrosis associated with afatinib: A case report and literature review
por: Yang, Wei, et al.
Publicado: (2023)

A Case of Rheumatoid Arthritis with Bucillamine-Induced Yellow Nail Syndrome Initially Manifesting as Pulmonary Disease
por: Isozaki, Takeo, et al.
Publicado: (2010)

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER2 oncogene alterations
por: Suzawa, Ken, et al.
Publicado: (2015)

Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low‐dose afatinib: A case report
por: Iida, Yuko, et al.
Publicado: (2019)

Successful Treatment of Afatinib Reversing Epidermal Growth Factor Receptor Exon19Deletion/G724S Mutation Resistance Guided by Protein‐Drug Docking
por: Yu, Nian, et al.
Publicado: (2021)

Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation
por: Kuo, Chih-Hsi Scott, et al.
Publicado: (2022)

Epidermal growth factor/epidermal growth factor receptor signaling blockage inhibits tumor cell‐derived exosome uptake by oral squamous cell carcinoma through macropinocytosis
por: Sasabe, Eri, et al.
Publicado: (2021)

Bucillamine-Induced Membranous Nephropathy with Crescent Formation in a Patient with Rheumatoid Arthritis: Case Report and Literature Review
por: Manabe, Shun, et al.
Publicado: (2014)

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
por: Creelan, Ben C., et al.
Publicado: (2019)

Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid
por: Ma, Chunhua, et al.
Publicado: (2019)

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancer
por: Sumi, Toshiyuki, et al.
Publicado: (2021)

Metabolic complete tumor response in a patient with epidermal growth factor receptor mutant non-small cell lung cancer treated with a reduced dose of afatinib
por: Puliafito, Ivana, et al.
Publicado: (2022)

Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study
por: Fujii, Hiroaki, et al.
Publicado: (2022)

Inhibiting Epidermal Growth Factor Receptor at a Distance
por: Sinclair, Julie K.-L., et al.
Publicado: (2014)

Bucillamine-induced Pneumonitis in a Patient with Rheumatoid Arthritis-associated Interstitial Pneumonia: A Case Report and Review of the Literature
por: Fukada, Atsuki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8ocgfbk694sb47nmuefsf4ntv8